- General information enquiries
- Call 00 800 6 7 8 9 10 11
- E-mail your questions
European Commission
Public Health
Accessibility tools
Service tools
Language selector
- Current languageen
Navigation path
- European Commission
- Public health
- Reference documents
- Register
- Orphan products
- Vaccine consisting of 5 survivin peptides with different hum
Pharmaceuticals - Community Register
Community register of orphan medicinal products | GRANTED |
Product information |
Vaccine consisting of 5 survivin peptides with different human leukocyte antigen restrictions
| EU orphan designation number: | EU/3/16/1791
|
| Active ingredient: | Vaccine consisting of 5 survivin peptides with different human leukocyte antigen restrictions |
| Indication: | Treatment of ovarian cancer |
| Sponsor: | Dr Ulrich Granzer
Mauerkircherstrasse 105, 81925 München, Deutschland |
Public summary of scientific opinion
European Commission procedures |
| Close date procedure | Procedure type | EMEA number | Decision | summary publ | decision docs | annex |
| 22/11/2016 | Orphan designation | EMA/OD/159/16 | (2016)7635 of 18/11/2016 |
CONTACT
EU links
Directorate General Health & Consumers